Analysis of the dosage cycle and dosage standard of a box of Lynparza

Olaparib is an oral PARP inhibitor, mainly used for patients with ovarian cancer, breast cancer and some prostate cancer who carry BRCA gene mutations. Its mechanism of action is to inhibit the activity of polyADPribose polymerase (PARP), making tumor cellsDNA damaged beyond repair, thereby inducing tumor cell apoptosis. Lynparza is suitable for patients who have previously received chemotherapy or have refractory tumors. It can be used as a single agent or in combination with chemotherapy or targeted drugs in specific regimens.

The usual dose of olaparib is300mg taken orally twice daily, usually in tablet form. The dose can be individually adjusted based on the patient's weight, liver and kidney function, and tolerance. When some patients experience adverse reactions, doctors may adjust the dose to 250mg or 200mg twice a day to ensure efficacy while mitigating side effects. Patients should strictly follow the doctor's instructions to take medication and avoid missing doses or increasing or decreasing the dosage on their own.

Olaparib is usually sold in packs containing 60 tablets or 112 tablets. Taking 60 tablet packaging as an example, the standard dose is 300mg twice a day (two tablets each time, a total of four tablets per day). One box of medicine can last for about 15 days of treatment; if the dosage is adjusted according to the guidance of a doctor or the number of daily doses is reduced, the cycle can be extended accordingly. The doctor will determine the specific dosage cycle based on the patient's disease status, tolerance and efficacy evaluation, and will follow up regularly to evaluate the efficacy and side effects.

While taking Lynparza, patients should maintain regular medication schedules, avoid missing doses, and pay attention to adverse reactions, such as nausea, fatigue, bone marrow suppression, and abnormal liver function. If serious side effects occur, the doctor should be informed promptly and the dose should be adjusted or treatment suspended if necessary. In addition, blood routine, liver and kidney function and tumor markers need to be reviewed regularly during medication to ensure drug efficacy and safety. Following the doctor's guidance and properly arranging the cycle and dosage is the key to achieving the best efficacy of Lynparza.

Reference materials:https://www.drugs.com/